New Meta-Analysis Confirms Effectiveness of BioGaia’s Probiotic for Infant Colic

Guía de Regalos

STOCKHOLM–(BUSINESS WIRE)–Regulatory News:

BioGaia (STO:BIOGB)

In a newly published systematic review the proof of effect on infant
colic was further strengthened for L. reuteri Protectis. The review
evaluated 17 studies of different treatments of infant colic, whereof L.
reuteri Protectis was the only probiotic. Only one other product was
deemed effective. Simethicone, a drug often prescribed for colic, was
shown to have no effect.

Prior to the new review four meta-analyses, evaluating different
probiotics as well as non-probiotic treatments, have come to the same
conclusion; that L. reuteri Protectis is effective in colic, especially
in breastfed and mixed fed infants. In the new, fifth review, with 6
studies on L. reuteri Protectis included, the proof was further
strengthened.

”The new meta-analysis once again confirms our position as the number
one treatment for infants with colic. Today health care professionals
around the world can be totally reassured that they are suggesting an
effective treatment when recommending BioGaia ProTectis drops to their
patients”, says Peter Rothschild, President, BioGaia.

The systematic review and meta-analysis was published online by
researchers Tracey Harb and colleagues at University of Queensland,
Australia, in Journal of Pediatric Gastroenterology and Nutrition 14
December 2015.

Latest press releases from BioGaia

2016-01-08 BioGaia’s subsidiary IBT has US IND open and Swedish CTA¹
approved for clinical study

2015-12-01 BioGaia makes further investments in MetaboGen

2015-10-26 BioGaia signs exclusive agreement in Sri Lanka

BioGaia has published this information in accordance with the Swedish
Securities Market Act. The information was issued for publication on 11
January 2016, 11:00 am CET.

BioGaia is a healthcare company that develops, markets and sells
probiotic products with documented health benefits. The products are
primarily based on the lactic acid bacterium Lactobacillus reuteri,
which has probiotic, health-enhancing effects. The class B share of the
Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ
OMX Nordic Exchange Stockholm. www.biogaia.com

This information was brought to you by Cision http://news.cision.com

Contacts

BioGaia
Peter Rothschild, President
+46 8 555 293 00